Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fluorine-containing compound modified cationic polymer in preparation of vaccine drugs

A technology of cationic polymers and compounds, which is applied in the fields of polymer chemistry and medical biomaterials, and can solve problems such as the reduction of vaccination efficiency

Active Publication Date: 2020-10-30
SUZHOU UNIV
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, antigen delivery by subcutaneous injection will bypass immune cells, resulting in less efficient vaccination, and the proper method of administering the vaccine to the appropriate site will elicit a strong immune response with a much lower dose of antigen than an intramuscular vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fluorine-containing compound modified cationic polymer in preparation of vaccine drugs
  • Application of fluorine-containing compound modified cationic polymer in preparation of vaccine drugs
  • Application of fluorine-containing compound modified cationic polymer in preparation of vaccine drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1: prepare the chitosan (deacetylation degree ≥ 95%, viscosity 100-200mpa.s) of the different degree of modification of perfluoroheptanoic acid, wherein the molar ratio of perfluoroheptanoic acid and N-glucosamine unit is respectively 1: 2.2, 1:4.2, 1:8.4, 1:16.8.

[0072] Synthesis method: (1) Preparation of chitosan acetic acid aqueous solution: take 200 mg of fully dried chitosan and add it to 10 ml of 1% acetic acid aqueous solution, stir for 30 min to fully dissolve, then slowly add 1.6 ml of 0.5 M sodium hydroxide dropwise, stir Until the solution is clear and the pH is around 6.5. Prepare 4 parts of chitosan acetic acid aqueous solution in this way. (2) Activation of perfluoroheptanoic acid (13 fluoroheptanoic acid): Weigh 206mg, 103mg, 51.5mg, and 26mg of perfluoroheptanoic acid respectively, dissolve them in an appropriate amount of anhydrous dimethyl sulfoxide, and add appropriate amount of EDC in turn , NHS in the dark and stirred for 1h. (3) Pr...

Embodiment 2

[0074] Example 2: 1. Fluorinated chitosan-chicken ovalbumin complexes were prepared with perfluoroheptanoic acid-modified chitosan as a carrier, incubated with bone marrow-derived dendritic cells, and investigated to stimulate the maturation of dendritic cells by the complexes Ability.

[0075] specific method:

[0076] Preparation of perfluoroheptanoic acid-modified chitosan-chicken ovalbumin complex: Weigh 0.9 mg of perfluoroheptanoic acid-modified chitosan and dissolve it with 900 μL of ultrapure water, and drop 100 μL (20 mg / mL) of chicken ovalbumin, and continued to stir for one hour to obtain a perfluoroheptanoic acid-modified chitosan-chicken ovalbumin (FCS-OVA) complex.

[0077] Add 10 μL of the above-prepared complex to a 24-well plate, and add 1 mL of cell suspension containing 1 million dendrites. Incubate in a 37°C incubator for 24 hours, stain the dendritic cells with FITC-CD11c, PE-CD86, and APC-CD80, analyze the fluorescence signal of FITC with flow cytometry...

Embodiment 3

[0096] Embodiment 3: prepare the chitosan (deacetylation degree ≥ 95%, viscosity 100-200mpa.s) of the different modification degree of 3-fluorobenzoic acid, wherein the feeding molar ratio of 3-fluorobenzoic acid and N-glucosamine unit is respectively 1:2.1, 1:4.2, 1:8.4, 1:16.8.

[0097] Synthetic method: (1) Preparation of chitosan acetic acid aqueous solution: Weigh 200 mg of fully dried chitosan and add it to 10 ml of 1% acetic acid aqueous solution. Of course, hydrochloric acid aqueous solution can also be used. Stir for 30 minutes to fully dissolve, then slowly add 1.6 ml of 0.5 M sodium hydroxide, stirred until the solution was clear and the pH was around 6.5. Simply consider the angle sodium hydroxide of alkalization solution and can be replaced by alkalis such as ammoniacal liquor, triethylamine, but the by-product that uses sodium hydroxide is sodium chloride from the product process angle, is more suitable for industrialization. Prepare 4 parts of chitosan acetic a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of fluorine-containing compound modified cationic polymer in preparation of vaccine drugs. The cationic polymer comprises a transdermal vaccine vector (a), wherein the transdermal vaccine vector (a) is a cationic polymer modified by a fluorine-containing compound; the cationic polymer modified by the fluorine-containing compound is fluorinated chitosan; a fluorine-containing compound is covalently connected to a main chain of chitosan, the molecular weight range of the chitosan is 1000-5000000, the deacetylation degree of the chitosan is not less than 55%, the viscosity range of the chitosan is 25-1000 centipoises, and the transdermal vaccine carrier has three antigen permeation paths including intracellular permeation, intercellular permeation and hair follicle permeation. Fluorinated chitosan is a very good immunologic adjuvant, can non-specifically stimulate an immune system, can effectively induce cytotoxic macrophages and cell-mediated immuneand circulating antibody formation, and amplifies immune response. The biocompatibility is good, and the huge commercial value is realized.

Description

technical field [0001] The invention relates to the technical fields of polymer chemistry and medical biomaterials, in particular to a cationic polymer modified with a fluorine-containing compound as a carrier and adjuvant for various vaccinations. Background technique [0002] Vaccines are biological agents that increase immunity against specific diseases. The traditional types of vaccines that have been used clinically to date are those containing dead or attenuated microorganisms, inactivated toxins (toxoids), protein subunits, and polysaccharide antigens or combinations Vaccines for substances that resemble disease-causing microbes and stimulate the body's immune system to recognize them as foreign, destroy them and "remember". Vaccination is the most effective means of controlling morbidity and mortality associated with infectious diseases, and its benefits have been recognized globally for many years. The success of initiatives such as smallpox eradication, polio and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C08B37/08A61K47/36A61K31/704A61P35/00
CPCC08B37/003A61K47/36A61K31/704A61P35/00Y02A50/30A61K31/196A61K9/0014A61K9/0048A61K8/492A61Q19/00A61K2800/10A61K8/736A61Q7/00A61K8/43A61K8/606A61K8/44A61Q19/02A61K2800/56A61K2800/54C08L5/08A61K47/61A61K47/542A61K47/54
Inventor 刘庄陈倩肖志晟金秋桐赵琪
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products